Loren K Mell1, Ronghui Xu2, Catheryn M Yashar3, Michael T McHale4, John P Einck3, Jyoti Mayadev5, Euyhyun Lee6, Pratibha Binder4, Dominique Rash3, Ramez Eskander4, Elena S Heide7, Steven C Plaxe4, Arno J Mundt5, Cheryl C Saenz4. 1. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California; Center for Precision Radiation Medicine, La Jolla, California. Electronic address: lmell@ucsd.edu. 2. Department of Family Medicine and Public Health and Department of Mathematics, University of California San Diego, La Jolla, California. 3. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California. 4. Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of California San Diego, La Jolla, California. 5. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California; Center for Precision Radiation Medicine, La Jolla, California. 6. Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla, California. 7. Center for Precision Radiation Medicine, La Jolla, California.
Abstract
PURPOSE: The use of concurrent doublet chemotherapy with radiation for locoregionally advanced cervical cancer (LACC) is limited by gastrointestinal and hematologic toxicity. By reducing radiation dose to bowel and bone marrow, image guided intensity modulated radiation therapy (IG-IMRT) may improve chemotherapy tolerance. The goal of this study was to determine whether IG-IMRT could lead to improved tolerance to concurrent cisplatin and gemcitabine for LACC. METHODS AND MATERIALS: We conducted an open-label, nonrandomized, prospective phase 1 dose escalation trial at a tertiary academic cancer center (ClinicalTrials.gov identifier: NCT01554410). We enrolled patients with stage IB-IVA cervical cancer, with either an intact cervix or posthysterectomy with residual/recurrent pelvic or paraortic nodal involvement, undergoing radical pelvic or extended field chemoradiation therapy. Treatment consisted of chemoradiation with IG-IMRT (45-47.6 Gy, 25-28 fractions to the pelvis ± paraortic nodes with simultaneous nodal boost to 53.2-59.4 Gy, 28 fractions) plus 5 cycles of concurrent weekly cisplatin 40 mg/m2 with escalating doses of gemcitabine (50, 75, 100, or 125 mg/m2). Cohorts were separated preregistration according to whether the patient received pelvic or extended field IG-IMRT and whether gemcitabine followed (CG) or preceded (GC) cisplatin delivery. Dose-limiting toxicity (DLT) events were monitored up to 30 days after chemoradiation therapy. The primary endpoint was maximum tolerated dose (MTD) resulting in DLT probability ≤20%. RESULTS: Between February 2011 and June 2019, 35 patients were registered. Overall, 7 patients (20.0%) experienced DLTs. For the pelvic field cohort, the estimated MTD was 100 mg/m2 with GC sequencing, which is higher than the previously reported MTD for this regimen. The extended field cohort was closed after 2 of 3 patients experienced a DLT at the first dose level. CONCLUSIONS: IG-IMRT can permit higher doses of concurrent gemcitabine with cisplatin and pelvic radiation for LACC. However, acute toxicity remains a factor with this regimen, depending on radiation volume and chemotherapy sequencing.
PURPOSE: The use of concurrent doublet chemotherapy with radiation for locoregionally advanced cervical cancer (LACC) is limited by gastrointestinal and hematologic toxicity. By reducing radiation dose to bowel and bone marrow, image guided intensity modulated radiation therapy (IG-IMRT) may improve chemotherapy tolerance. The goal of this study was to determine whether IG-IMRT could lead to improved tolerance to concurrent cisplatin and gemcitabine for LACC. METHODS AND MATERIALS: We conducted an open-label, nonrandomized, prospective phase 1 dose escalation trial at a tertiary academic cancer center (ClinicalTrials.gov identifier: NCT01554410). We enrolled patients with stage IB-IVA cervical cancer, with either an intact cervix or posthysterectomy with residual/recurrent pelvic or paraortic nodal involvement, undergoing radical pelvic or extended field chemoradiation therapy. Treatment consisted of chemoradiation with IG-IMRT (45-47.6 Gy, 25-28 fractions to the pelvis ± paraortic nodes with simultaneous nodal boost to 53.2-59.4 Gy, 28 fractions) plus 5 cycles of concurrent weekly cisplatin 40 mg/m2 with escalating doses of gemcitabine (50, 75, 100, or 125 mg/m2). Cohorts were separated preregistration according to whether the patient received pelvic or extended field IG-IMRT and whether gemcitabine followed (CG) or preceded (GC) cisplatin delivery. Dose-limiting toxicity (DLT) events were monitored up to 30 days after chemoradiation therapy. The primary endpoint was maximum tolerated dose (MTD) resulting in DLT probability ≤20%. RESULTS: Between February 2011 and June 2019, 35 patients were registered. Overall, 7 patients (20.0%) experienced DLTs. For the pelvic field cohort, the estimated MTD was 100 mg/m2 with GC sequencing, which is higher than the previously reported MTD for this regimen. The extended field cohort was closed after 2 of 3 patients experienced a DLT at the first dose level. CONCLUSIONS: IG-IMRT can permit higher doses of concurrent gemcitabine with cisplatin and pelvic radiation for LACC. However, acute toxicity remains a factor with this regimen, depending on radiation volume and chemotherapy sequencing.
Authors: J R Kroep; G J Peters; C J van Moorsel; A Catik; J B Vermorken; H M Pinedo; C J van Groeningen Journal: Ann Oncol Date: 1999-12 Impact factor: 32.976
Authors: Samantha Cabral S da Costa; Renata Colombo Bonadio; Flavia Carolina G Gabrielli; Andrea S Aranha; Maria Luiza N Dias Genta; Vanessa C Miranda; Daniela de Freitas; Elias Abdo Filho; Patrícia A O Ferreira; Karime K Machado; Mariana Scaranti; Heloísa de A Carvalho; Maria Del Pilar Estevez-Diz Journal: J Clin Oncol Date: 2019-08-26 Impact factor: 44.544
Authors: Ann H Klopp; Anamaria R Yeung; Snehal Deshmukh; Karen M Gil; Lari Wenzel; Shannon N Westin; Kent Gifford; David K Gaffney; William Small; Spencer Thompson; Desiree E Doncals; Guilherme H C Cantuaria; Brian P Yaremko; Amy Chang; Vijayananda Kundapur; Dasarahally S Mohan; Michael L Haas; Yong Bae Kim; Catherine L Ferguson; Stephanie L Pugh; Lisa A Kachnic; Deborah W Bruner Journal: J Clin Oncol Date: 2018-07-10 Impact factor: 44.544
Authors: Loren K Mell; Igor Sirák; Lichun Wei; Rafal Tarnawski; Umesh Mahantshetty; Catheryn M Yashar; Michael T McHale; Ronghui Xu; Gordon Honerkamp-Smith; Ruben Carmona; Mary Wright; Casey W Williamson; Linda Kasaová; Nan Li; Stephen Kry; Jeff Michalski; Walter Bosch; William Straube; Julie Schwarz; Jessica Lowenstein; Steve B Jiang; Cheryl C Saenz; Steve Plaxe; John Einck; Chonlakiet Khorprasert; Paul Koonings; Terry Harrison; Mei Shi; A J Mundt Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-23 Impact factor: 7.038
Authors: Lucas K Vitzthum; Helen Park; Kaveh Zakeri; Elena S Heide; Vinit Nalawade; Arno J Mundt; Florin Vaida; James D Murphy; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2019-10-11 Impact factor: 7.038
Authors: Casey W Williamson; Igor Sirák; Ronghui Xu; Lorraine Portelance; Lichun Wei; Rafal Tarnawski; Umesh Mahantshetty; Elena S Heide; Catheryn M Yashar; Michael T McHale; Walter Bosch; Jessica Lowenstein; Cheryl C Saenz; Steve Plaxe; Ramez Eskander; John Einck; Arno J Mundt; Jyoti Mayadev; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-20 Impact factor: 7.038